|
1
|
Zhao LY, Song J, Liu Y, Song CX and Yi C:
Mapping the epigenetic modifications of DNA and RNA. Protein Cell.
11:792–808. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Toh TB, Lim JJ and Chow EK: Epigenetics in
cancer stem cells. Mol Cancer. 16:292017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Orsolic I, Carrier A and Esteller M:
Genetic and epigenetic defects of the RNA modification machinery in
cancer. Trends Genet. 39:74–88. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Z, Zhong X, Xia M and Zhong J: The
roles and mechanisms of the m6A reader protein YTHDF1 in tumor
biology and human diseases. Mol Ther Nucleic Acids. 26:1270–1279.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao BS, Roundtree IA and He C:
Post-transcriptional gene regulation by mRNA modifications. Nat Rev
Mol Cell Biol. 18:31–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Machnicka MA, Milanowska K, Osman Oglou O,
Purta E, Kurkowska M, Olchowik A, Januszewski W, Kalinowski S,
Dunin-Horkawicz S, Rother KM, et al: MODOMICS: A database of RNA
modification pathways-2013 update. Nucleic Acids Res. 41((Database
Issue)): D262–D267. 2013.PubMed/NCBI
|
|
7
|
Desrosiers R, Friderici K and Rottman F:
Identification of methylated nucleosides in messenger RNA from
Novikoff hepatoma cells. Proc Natl Acad Sci USA. 71:3971–3975.
1974. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ke S, Alemu EA, Mertens C, Gantman EC, Fak
JJ, Mele A, Haripal B, Zucker-Scharff I, Moore MJ, Park CY, et al:
A majority of m6A residues are in the last exons, allowing the
potential for 3′ UTR regulation. Genes Dev. 29:2037–2053. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dominissini D, Moshitch-Moshkovitz S,
Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K,
Jacob-Hirsch J, Amariglio N, Kupiec M, et al: Topology of the human
and mouse m6A RNA methylomes revealed by m6A-seq. Nature.
485:201–206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu S, Li X, Liu S, Yang R, Liu X and Wu S:
N6-methyladenosine: A novel RNA imprint in human cancer.
Front Oncol. 9:14072019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen C, Yuan W, Zhou Q, Shao B, Guo Y,
Wang W, Yang S, Guo Y, Zhao L, Dang Q, et al:
N6-methyladenosine-induced circ1662 promotes metastasis of
colorectal cancer by accelerating YAP1 nuclear localization.
Theranostics. 11:4298–4315. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roignant JY and Soller M: m6A
in mRNA: An ancient mechanism for fine-tuning gene expression.
Trends Genet. 33:380–390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nielsen J, Christiansen J, Lykke-Andersen
J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like
growth factor II mRNA-binding proteins represses translation in
late development. Mol Cell Biol. 19:1262–1270. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao J, Mu Q and Huang H: The roles of
insulin-like growth factor 2 mRNA-binding protein 2 in cancer and
cancer stem cells. Stem Cells Int. 2018:42172592018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui XH, Hu SY, Zhu CF and Qin XH:
Expression and prognostic analyses of the insulin-like growth
factor 2 mRNA binding protein family in human pancreatic cancer.
BMC Cancer. 20:11602020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dai N, Rapley J, Angel M, Yanik MF, Blower
MD and Avruch J: mTOR phosphorylates IMP2 to promote IGF2 mRNA
translation by internal ribosomal entry. Genes Dev. 25:1159–1172.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Chen L and Qiang P: The role of
IGF2BP2, an m6A reader gene, in human metabolic diseases and
cancers. Cancer Cell Int. 21:992021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Li Y and Lu H: [ARTICLE WITHDRAWN]
miR-1193 suppresses proliferation and invasion of human breast
cancer cells through directly targeting IGF2BP2. Oncol Res.
25:579–585. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu XL, Lu RY, Wang LK, Wang YY, Dai YJ,
Wang CY, Yang YJ, Guo F, Xue J and Yang DD: Long noncoding RNA
HOTAIR silencing inhibits invasion and proliferation of human colon
cancer LoVo cells via regulating IGF2BP2. J Cell Biochem.
120:1221–1231. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nielsen J, Kristensen MA, Willemoës M,
Nielsen FC and Christiansen J: Sequential dimerization of human
zipcode-binding protein IMP1 on RNA: A cooperative mechanism
providing RNP stability. Nucleic Acids Res. 32:4368–4376. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li N, Deng L, Zhang Y, Tang X, Lei B and
Zhang Q: IGF2BP2 modulates autophagy and serves as a prognostic
marker in glioma. Ibrain. 10:19–33. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lv L, Zhang X, Liu Y, Zhu X, Pan R and
Huang L: Three liquid-liquid phase separation-related genes
associated with prognosis in glioma. Pharmgenomics Pers Med.
17:171–181. 2024.PubMed/NCBI
|
|
23
|
Hu Y, Chen J, Liu M, Feng Q and Peng H:
IGF2BP2 serves as a core m6A regulator in head and neck squamous
cell carcinoma. Biosci Rep. 42:BSR202213112022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deng X, Jiang Q, Liu Z and Chen W:
Clinical significance of an m6A reader gene, IGF2BP2, in head and
neck squamous cell carcinoma. Front Mol Biosci. 7:682020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang X, Tang Q, Li S, Li M and Yang T:
IGF2BP2 acts as a m6A modification regulator in
laryngeal squamous cell carcinoma through facilitating CDK6 mRNA
stabilization. Cell Death Discov. 9:3712023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin SH, Lin CW, Lu JW, Yang WE, Lin YM, Lu
HJ and Yang SF: Cytoplasmic IGF2BP2 protein expression in human
patients with oral squamous cell carcinoma: Prognostic and clinical
implications. Int J Med Sci. 19:1198–1204. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barghash A, Golob-Schwarzl N, Helms V,
Haybaeck J and Kessler SM: Elevated expression of the IGF2 mRNA
binding protein 2 (IGF2BP2/IMP2) is linked to short survival and
metastasis in esophageal adenocarcinoma. Oncotarget. 7:49743–49750.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu F, Chen W, Jiang T, Cheng C, Wang B, Lu
Z, Huang G, Qiu J, Wei W, Yang M and Huang X: Expression profile,
clinical significance and biological functions of IGF2BP2 in
esophageal squamous cell carcinoma. Exp Ther Med. 23:2522022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deng H, Yao H, Zhou S, He C, Huang Y, Li
Y, Chen H and Shu J: Pancancer analysis uncovers an immunological
role and prognostic value of the m6A reader IGF2BP2 in pancreatic
cancer. Mol Cell Probes. 73:1019482024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dahlem C, Barghash A, Puchas P, Haybaeck J
and Kessler SM: The insulin-like growth factor 2 mRNA binding
protein IMP2/IGF2BP2 is overexpressed and correlates with poor
survival in pancreatic cancer. Int J Mol Sci. 20:32042019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang JY, Chan EK, Peng XX and Tan EM: A
novel cytoplasmic protein with RNA-binding motifs is an autoantigen
in human hepatocellular carcinoma. J Exp Med. 189:1101–1110. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu M, Nakamura RM, Dent ED, Zhang JY,
Nielsen FC, Christiansen J, Chan EK and Tan EM: Aberrant expression
of fetal RNA-binding protein p62 in liver cancer and liver
cirrhosis. Am J Pathol. 159:945–953. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X,
Zhang X, Cao Y, Ma D, Zhu X, et al: m6A-dependent
glycolysis enhances colorectal cancer progression. Mol Cancer.
19:722020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gong L, Liu Q, Jia M and Sun X: Systematic
analysis of IGF2BP family members in non-small-cell lung cancer.
Hum Genomics. 18:632024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jia M, Shi Y, Xie Y, Li W, Deng J, Fu D,
Bai J, Ma Y, Zuberi Z, Li J and Li Z: WT1-AS/IGF2BP2 axis is a
potential diagnostic and prognostic biomarker for lung
adenocarcinoma according to ceRNA network comprehensive analysis
combined with experiments. Cells. 11:252021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Almawi WY, Zidi S, Sghaier I, El-Ghali RM,
Daldoul A and Midlenko A: Novel association of IGF2BP2 gene
variants with altered risk of breast cancer and as potential
molecular biomarker of triple negative breast cancer. Clin Breast
Cancer. 23:272–280. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yuan J, Li X, Wang F, Liu H, Guan W and Xu
G: Insulin-like growth factor 2 mRNA-binding protein 2 is a
therapeutic target in ovarian cancer. Exp Biol Med (Maywood).
248:2198–2209. 2023.PubMed/NCBI
|
|
38
|
Yang L, Liu J, Jin Y, Xing J, Zhang J,
Chen X and Yu A: Synchronous profiling of mRNA N6-methyladenosine
modifications and mRNA expression in high-grade serous ovarian
cancer: A pilot study. Sci Rep. 14:104272024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He X, Li W, Liang X, Zhu X, Zhang L, Huang
Y, Yu T, Li S and Chen Z: IGF2BP2 overexpression indicates poor
survival in patients with acute myelocytic leukemia. Cell Physiol
Biochem. 51:1945–1956. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Feng P, Chen D, Wang X, Li Y, Li Z, Li B,
Zhang Y, Li W, Zhang J, Ye J, et al: Inhibition of the
m6A reader IGF2BP2 as a strategy against T-cell acute
lymphoblastic leukemia. Leukemia. 36:2180–2188. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou W, Gao Q, He C, Wang L, Wang Y, Feng
L, Li W, Liu W, Ma R and Liu L: Association between polymorphism in
diabetes susceptibility gene insulin-like growth factor
2mRNA-binding protein 2 and risk of diffuse large B-cell lymphoma.
Clin Med Insights Oncol. 17:117955492312011282023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao Y, Zhou Y, Qian Y, Wei W, Lin X, Mao
S, Sun J and Jin J: m6A-dependent upregulation of DDX21
by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates
progression of acute myeloid leukaemia. Clin Transl Med.
14:e16282024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Song T, Hu Z, Zeng C, Luo H and Liu J:
FLOT1, stabilized by WTAP/IGF2BP2 mediated N6-methyladenosine
modification, predicts poor prognosis and promotes growth and
invasion in gliomas. Heliyon. 9:e162802023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yu D, Pan M, Li Y, Lu T, Wang Z, Liu C and
Hu G: RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic
metastasis and epithelial-mesenchymal transition of head and neck
squamous carcinoma cells via stabilizing slug mRNA in an
m6A-dependent manner. J Exp Clin Cancer Res. 41:62022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liang J, Cai H, Hou C, Song F, Jiang Y,
Wang Z, Qiu D, Zhu Y, Wang F, Yu D and Hou J: METTL14 inhibits
malignant progression of oral squamous cell carcinoma by targeting
the autophagy-related gene RB1CC1 in an m6A-IGF2BP2-dependent
manner. Clin Sci (Lond). 137:1373–1389. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Leng F, Miu YY, Zhang Y, Luo H, Lu XL,
Cheng H and Zheng ZG: A micro-peptide encoded by HOXB-AS3 promotes
the proliferation and viability of oral squamous cell carcinoma
cell lines by directly binding with IGF2BP2 to stabilize c-Myc.
Oncol Lett. 22:6972021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu L, Li Q, Wang Y, Wang L, Guo Y, Yang R,
Zhao N, Ge N, Wang Y and Guo C: m6A methyltransferase
METTL3 promotes oral squamous cell carcinoma progression through
enhancement of IGF2BP2-mediated SLC7A11 mRNA stability. Am J Cancer
Res. 11:5282–5298. 2021.PubMed/NCBI
|
|
49
|
Lin CW, Yang WE, Su CW, Lu HJ, Su SC and
Yang SF: IGF2BP2 promotes cell invasion and epithelial-mesenchymal
transition through Src-mediated upregulation of EREG in oral
cancer. Int J Biol Sci. 20:818–830. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dong L, Geng Z, Liu Z, Tao M, Pan M and Lu
X: IGF2BP2 knockdown suppresses thyroid cancer progression by
reducing the expression of long non-coding RNA HAGLR. Pathol Res
Pract. 225:1535502021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang W, Ding Y, Zhao Y and Li X: m6A
reader IGF2BP2 promotes lymphatic metastasis by stabilizing DPP4 in
papillary thyroid carcinoma. Cancer Gene Ther. 31:285–299. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zheng H, Cao Z, Lv Y and Cai X:
WTAP-mediated N6-methyladenine modification of circEEF2 promotes
lung adenocarcinoma tumorigenesis by stabilizing CANT1 in an
IGF2BP2-dependent manner. Mol Biotechnol. Apr 15–2024.(Epub ahead
of print). View Article : Google Scholar
|
|
53
|
Han L, Lei G, Chen Z, Zhang Y, Huang C and
Chen W: IGF2BP2 regulates MALAT1 by serving as an
N6-methyladenosine reader to promote NSCLC proliferation. Front Mol
Biosci. 8:7800892022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Huang GW, Chen QQ, Ma CC, Xie LH and Gu J:
linc01305 promotes metastasis and proliferation of esophageal
squamous cell carcinoma through interacting with IGF2BP2 and
IGF2BP3 to stabilize HTR3A mRNA. Int J Biochem Cell Biol.
136:1060152021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang C, Zhou M, Zhu P, Ju C, Sheng J, Du
D, Wan J, Yin H, Xing Y, Li H, et al: IGF2BP2-induced circRUNX1
facilitates the growth and metastasis of esophageal squamous cell
carcinoma through miR-449b-5p/FOXP3 axis. J Exp Clin Cancer Res.
41:3472022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhao R, Li T, Zhao X, Yang Z, Ma L and
Wang X: The m6A reader IGF2BP2 promotes the progression of
esophageal squamous cell carcinoma cells by increasing the
stability of OCT4 mRNA. Biochem Cell Biol. 102:169–178. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li Y, Xiao Z, Wang Y, Zhang D and Chen Z:
The m6A reader IGF2BP2 promotes esophageal cell carcinoma
progression by enhancing EIF4A1 translation. Cancer Cell Int.
24:1622024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang Z, Xing Y, Gao W, Yang L, Shi J,
Song W and Li T: N6-methyladenosine (m6A)
reader IGF2BP2 promotes gastric cancer progression via targeting
SIRT1. Bioengineered. 13:11541–11550. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shen H, Zhu H, Chen Y, Shen Z, Qiu W, Qian
C and Zhang J: ZEB1-induced LINC01559 expedites cell proliferation,
migration and EMT process in gastric cancer through recruiting
IGF2BP2 to stabilize ZEB1 expression. Cell Death Dis. 12:3492021.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ouyang J, Li J, Li D, Jiang J, Hao T, Xia
Y, Lu X, Zhang C and He Y: IGF2BP2 promotes epithelial to
mesenchymal transition and metastasis through stabilizing HMGA1
mRNA in gastric cancer. Cancers(Basel). 14:53812022.PubMed/NCBI
|
|
61
|
Liu D, Xia AD, Wu LP, Li S, Zhang K and
Chen D: IGF2BP2 promotes gastric cancer progression by regulating
the IGF1R-RhoA-ROCK signaling pathway. Cell Signal. 94:1103132022.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN,
Chen ZH, Zeng ZL, Wang F, Zheng J, et al: METTL3 facilitates tumor
progression via an m6A-IGF2BP2-dependent mechanism in
colorectal carcinoma. Mol Cancer. 18:1122019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yi J, Peng F, Zhao J and Gong X:
METTL3/IGF2BP2 axis affects the progression of colorectal cancer by
regulating m6A modification of STAG3. Sci Rep. 13:172922023.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cui J, Tian J, Wang W, He T, Li X, Gu C,
Wang L, Wu J and Shang A: IGF2BP2 promotes the progression of
colorectal cancer through a YAP-dependent mechanism. Cancer Sci.
112:4087–4099. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bian Y, Wang Y, Xu S, Gao Z, Li C, Fan Z,
Ding J and Wang K: m6A Modification of Long Non-Coding
RNA HNF1A-AS1 Facilitates Cell Cycle Progression in Colorectal
Cancer via IGF2BP2-Mediated CCND1 mRNA Stabilization. Cells.
11:30082022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hou P, Meng S, Li M, Lin T, Chu S, Li Z,
Zheng J, Gu Y and Bai J: Correction to: LINC00460/DHX9/IGF2BP2
complex promotes colorectal cancer proliferation and metastasis by
mediating HMGA1 mRNA stability depending on m6A modification. J Exp
Clin Cancer Res. 40:3652021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Liu TY, Hu CC, Han CY, Mao SY, Zhang WX,
Xu YM, Sun YJ, Jiang DB, Zhang XY, Zhang JX, et al: IGF2BP2
promotes colorectal cancer progression by upregulating the
expression of TFRC and enhancing iron metabolism. Biol Direct.
18:192023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ye S, Song W, Xu X, Zhao X and Yang L:
IGF2BP2 promotes colorectal cancer cell proliferation and survival
through interfering with RAF-1 degradation by miR-195. FEBS Lett.
590:1641–1650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Liu K, Wei C, Yu H, Zhang Q and Du Z:
HMGA2 overexpression activates IGF2BP2 to stabilize APLP2 via m6A
modification and promote pancreatic cancer progression. Heliyon.
10:e272682024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cao P, Wu Y, Sun D, Zhang W, Qiu J, Tang
Z, Xue X and Qin L: IGF2BP2 promotes pancreatic carcinoma
progression by enhancing the stability of B3GNT6 mRNA via m6A
methylation. Cancer Med. 12:4405–4420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cai H, Zhao J, Zhang Q, Wu H, Sun Y, Guo
F, Zhou Y, Qin G, Xia W, Zhao Y, et al: Ubiquitin ligase TRIM15
promotes the progression of pancreatic cancer via the upregulation
of the IGF2BP2-TLR4 axis. Biochim Biophys Acta Mol Basis Dis.
1870:1671832024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Peng WX, Liu F, Jiang JH, Yuan H, Zhang Z,
Yang L and Mo YY: N6-methyladenosine modified LINC00901 promotes
pancreatic cancer progression through IGF2BP2/MYC axis. Genes Dis.
10:554–567. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lu J, Yu L, Xie N, Wu Y and Li B: METTL14
facilitates the metastasis of pancreatic carcinoma by stabilizing
LINC00941 in an m6A-IGF2BP2-dependent manner. J Cancer.
14:1117–1131. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Weng H, Feng W, Li F, Huang D, Lin L and
Wang Z: Transcription factor ETV1-induced lncRNA MAFG-AS1 promotes
migration, invasion, and epithelial-mesenchymal transition of
pancreatic cancer cells by recruiting IGF2BP2 to stabilize ETV1
expression. Growth Factors. 41:152–164. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhao C, Sun J, Dang Z, Su Q and Yang J:
Circ_0000775 promotes the migration, invasion and EMT of hepatic
carcinoma cells by recruiting IGF2BP2 to stabilize CDC27. Pathol
Res Pract. 235:1539082022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang X, Li Z, Nie H, Huang Y, Du J, Xi Y,
Guo C, Mu M, Li X, Zheng X, et al: The IGF2BP2-lncRNA TRPC7-AS1
axis promotes hepatocellular carcinoma cell proliferation and
invasion. Cell Signal. 117:1110782024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kessler SM, Laggai S, Barghash A,
Schultheiss CS, Lederer E, Artl M, Helms V, Haybaeck J and Kiemer
AK: IMP2/p62 induces genomic instability and an aggressive
hepatocellular carcinoma phenotype. Cell Death Dis. 6:e18942015.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Pu J, Wang J, Qin Z, Wang A, Zhang Y, Wu
X, Wu Y, Li W, Xu Z, Lu Y, et al: IGF2BP2 promotes liver cancer
growth through an m6A-FEN1-dependent mechanism. Front Oncol.
10:5788162020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Guan XQ, Yuan XN, Feng KX, Shao YC, Liu Q,
Yang ZL, Chen YY, Deng J, Hu MS, Li J, et al: IGF2BP2-modified
UBE2D1 interacts with Smad2/3 to promote the progression of breast
cancer. Am J Cancer Res. 13:2948–2968. 2023.PubMed/NCBI
|
|
80
|
Xia T, Dai XY, Sang MY, Zhang X, Xu F, Wu
J, Shi L, Wei JF and Ding Q: IGF2BP2 drives cell cycle progression
in triple-negative breast cancer by recruiting EIF4A1 to promote
the m6A-modified CDK6 translation initiation process. Adv Sci
(Weinh). 11:e23051422024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Li Y, Francia G and Zhang JY: p62/IMP2
stimulates cell migration and reduces cell adhesion in breast
cancer. Oncotarget. 6:32656–32668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Shi Y, Xiong X, Sun Y, Geng Z, Chen X, Cui
X, Lv J, Ge L, Jia X and Xu J: IGF2BP2 promotes ovarian cancer
growth and metastasis by upregulating CKAP2L protein expression in
an m6 A-dependent manner. FASEB J. 37:e231832023.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Shi R, Zhao R, Shen Y, Wei S, Zhang T,
Zhang J, Shu W, Cheng S, Teng H and Wang H: IGF2BP2-modified
circular RNA circCHD7 promotes endometrial cancer progression via
stabilizing PDGFRB and activating JAK/STAT signaling pathway.
Cancer Gene Ther. 31:1221–1236. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ji F, Lu Y, Chen S, Yu Y, Lin X, Zhu Y and
Luo X: IGF2BP2-modified circular RNA circARHGAP12 promotes cervical
cancer progression by interacting m6A/FOXM1 manner. Cell Death
Discov. 7:2152021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lang C, Yin C, Lin K, Li Y, Yang Q, Wu Z,
Du H, Ren D, Dai Y and Peng X: m6 A modification of
lncRNA PCAT6 promotes bone metastasis in prostate cancer through
IGF2BP2-mediated IGF1R mRNA stabilization. Clin Transl Med.
11:e4262021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
He P, Liu X, Yu G, Wang Y, Wang S, Liu J
and An Y: METTL3 facilitates prostate cancer progression via
inducing HOXC6 m6A modification and stabilizing its expression
through IGF2BP2-dependent mechanisms. Mol Cell Biochem.
479:1707–1720. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wang X, Hu M, Yu L, Wang X, Jiang X, Zhang
G and Ding K: The ‘m6A writer’ METTL3 and the ‘m6A reader’ IGF2BP2
regulate cutaneous T-cell lymphomas progression via CDKN2A. Hematol
Oncol. 40:567–576. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li J, Cao H, Yang J and Wang B: CircCDK1
blocking IGF2BP2-mediated m6A modification of CPPED1 promotes
laryngeal squamous cell carcinoma metastasis via the PI3K/AKT
signal pathway. Gene. 884:1476862023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Li J, Cao H, Yang J and Wang B:
IGF2BP2-m6A-circMMP9 axis recruits ETS1 to promote TRIM59
transcription in laryngeal squamous cell carcinoma. Sci Rep.
14:30142024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yu D, Xiao Z, Zou Z, Lin L, Li J, Tan J
and Chen W: IGF2BP2 promotes head and neck squamous carcinoma cell
proliferation and growth via the miR-98-5p/PI3K/Akt signaling
pathway. Front Oncol. 13:12529992023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Xu X, Yu Y, Zong K, Lv P and Gu Y:
Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic
cancer promotes cancer proliferation by activating the PI3K/Akt
signaling pathway. J Exp Clin Cancer Res. 38:4972019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Mu Q, Wang L, Yu F, Gao H, Lei T, Li P,
Liu P, Zheng X, Hu X, Chen Y, et al: Imp2 regulates GBM progression
by activating IGF2/PI3K/Akt pathway. Cancer Biol Ther. 16:623–633.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Latifkar A, Wang F, Mullmann JJ, Panizza
E, Fernandez IR, Ling L, Miller AD, Fischbach C, Weiss RS, Lin H,
et al: IGF2BP2 promotes cancer progression by degrading the RNA
transcript encoding a v-ATPase subunit. Proc Natl Acad Sci USA.
119:e22004771192022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kim HY, Ha Thi HT and Hong S: IMP2 and
IMP3 cooperate to promote the metastasis of triple-negative breast
cancer through destabilization of progesterone receptor. Cancer
Lett. 415:30–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Mao J, Qiu H and Guo L: LncRNA HCG11
mediated by METTL14 inhibits the growth of lung adenocarcinoma via
IGF2BP2/LATS1. Biochem Biophys Res Commun. 580:74–80. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Sun M, Zhang X, Bi F, Wang D, Zhou X, Li X
and Yang Q: FTO inhibits epithelial ovarian cancer progression by
destabilising SNAI1 mRNA through IGF2BP2. Cancers (Basel).
14:52182022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yan Y, Ma J, Chen Q, Zhang T, Fan R and Du
J: GAS5 regulated by FTO-mediated m6A modification suppresses cell
proliferation via the IGF2BP2/QKI axis in breast cancer. Discov
Oncol. 15:1822024. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ren J, Huang B, Li W, Wang Y, Pan X, Ma Q,
Liu Y, Wang X, Liang C, Zhang Y, et al: RNA-binding protein IGF2BP2
suppresses metastasis of clear cell renal cell carcinoma by
enhancing CKB mRNA stability and expression. Transl Oncol.
42:1019042024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Pan X, Huang B, Ma Q, Ren J, Liu Y, Wang
C, Zhang D, Fu J, Ran L, Yu T, et al: Circular RNA circ-TNPO3
inhibits clear cell renal cell carcinoma metastasis by binding to
IGF2BP2 and destabilizing SERPINH1 mRNA. Clin Transl Med.
12:e9942022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Wang G, Zhuang T, Zhen F, Zhang C, Wang Q,
Miao X, Qi N and Yao R: IGF2BP2 inhibits invasion and migration of
clear cell renal cell carcinoma via targeting Netrin-4 in an
m6A-dependent manner. Mol Carcinog. 63:1572–1587. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wu EY, Huang LP and Bao JH: miR-96-5p
regulates cervical cancer cell resistance to cisplatin by
inhibiting lncRNA TRIM52-AS1 and promoting IGF2BP2. Kaohsiung J Med
Sci. 38:1178–1189. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Fu L, Zhang D, Yi N, Cao Y, Wei Y, Wang W
and Li L: Circular RNA circPBX3 promotes cisplatin resistance of
ovarian cancer cells via interacting with IGF2BP2 to stabilize
ATP7A mRNA expression. Hum Cell. 35:1560–1576. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Xia C, Li Q, Cheng X, Wu T, Gao P and Gu
Y: Insulin-like growth factor 2 mRNA-binding protein 2-stabilized
long non-coding RNA Taurine up-regulated gene 1 (TUG1) promotes
cisplatin-resistance of colorectal cancer via modulating autophagy.
Bioengineered. 13:2450–2469. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Han J, Yu X, Wang S, Wang Y, Liu Q, Xu H
and Wang X: IGF2BP2 induces U251 glioblastoma cell chemoresistance
by inhibiting FOXO1-mediated PID1 expression through stabilizing
lncRNA DANCR. Front Cell Dev Biol. 9:6592282022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zhang M, Wang Q, Ke Z, Liu Y, Guo H, Fang
S and Lu K: LINC01001 promotes progression of crizotinib-resistant
NSCLC by modulating IGF2BP2/MYC axis. Front Pharmacol.
12:7592672021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wang J, Xu J and Zheng J: A1BG-AS1
promotes adriamycin resistance of breast cancer by recruiting
IGF2BP2 to upregulate ABCB1 in an m6A-dependent manner. Sci Rep.
13:207302023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sa R, Liang R, Qiu X, He Z, Liu Z and Chen
L: IGF2BP2-dependent activation of ERBB2 signaling contributes to
acquired resistance to tyrosine kinase inhibitor in differentiation
therapy of radioiodine-refractory papillary thyroid cancer. Cancer
Lett. 527:10–23. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wang X, Li X, Zhou Y, Huang X and Jiang X:
Long non-coding RNA OIP5-AS1 inhibition upregulates microRNA-129-5p
to repress resistance to temozolomide in glioblastoma cells via
downregulating IGF2BP2. Cell Biol Toxicol. 38:963–977. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Shi SJ, Han DH, Zhang JL, Li Y, Yang AG
and Zhang R: VIM-AS1 promotes proliferation and drives enzalutamide
resistance in prostate cancer via IGF2BP2-mediated HMGCS1 mRNA
stabilization. Int J Oncol. 62:342023. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Dong FL, Xu ZZ, Wang YQ, Li T, Wang X and
Li J: Exosome-derived circUPF2 enhances resistance to targeted
therapy by redeploying ferroptosis sensitivity in hepatocellular
carcinoma. J Nanobiotechnology. 22:2982024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kendzia S, Franke S, Kröhler T,
Golob-Schwarzl N, Schweiger C, Toeglhofer AM, Skofler C, Uranitsch
S, El-Heliebi A, Fuchs J, et al: A combined computational and
functional approach identifies IGF2BP2 as a driver of
chemoresistance in a wide array of pre-clinical models of
colorectal cancer. Mol Cancer. 22:892023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhou Z, Zhang B, Deng Y, Deng S, Li J, Wei
W, Wang Y, Wang J, Feng Z, Che M, et al: FBW7/GSK3β mediated
degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback
loop and radioresistance in lung cancer. J Exp Clin Cancer Res.
43:342024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Hu P, Lin L, Huang T, Li Z, Xiao M, Guo H,
Chen G, Liu D, Ke M, Shan H, et al: Circular RNA circEYA3 promotes
the radiation resistance of hepatocellular carcinoma via the
IGF2BP2/DTX3L axis. Cancer Cell Int. 23:3082023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kim J and DeBerardinis RJ: Mechanisms and
implications of metabolic heterogeneity in cancer. Cell Metab.
30:434–446. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wu S, Chi C, Weng S, Zhou W and Liu Z:
IGF2BP2 promotes lncRNA DANCR stability mediated glycolysis and
affects the progression of FLT3-ITD + acute myeloid leukemia.
Apoptosis. 28:1035–1047. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zhou J, Zhang H, Zhong K, Tao L, Lin Y,
Xie G, Tan Y, Wu Y, Lu Y, Chen Z, et al: N6-methyladenosine
facilitates mitochondrial fusion of colorectal cancer cells via
induction of GSH synthesis and stabilization of OPA1 mRNA. Natl Sci
Rev. 11:nwae0392024. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wang J, Zhu M, Zhu J, Li J, Zhu X, Wang K,
Shen K, Yang K, Ni X, Liu X, et al: HES1 promotes aerobic
glycolysis and cancer progression of colorectal cancer via
IGF2BP2-mediated GLUT1 m6A modification. Cell Death Discov.
9:4112023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wang Y, Lu JH, Wu QN, Jin Y, Wang DS, Chen
YX, Liu J, Luo XJ, Meng Q, Pu HY, et al: LncRNA LINRIS stabilizes
IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer.
Mol Cancer. 18:1742019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yang K, Zhong Z, Zou J, Liao JY, Chen S,
Zhou S, Zhao Y, Li J, Yin D, Huang K and Li Y: Glycolysis and tumor
progression promoted by the m6A writer VIRMA via
m6A-dependent upregulation of STRA6 in pancreatic ductal
adenocarcinoma. Cancer Lett. 590:2168402024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Hu C, Liu T, Han C, Xuan Y, Jiang D, Sun
Y, Zhang X, Zhang W, Xu Y, Liu Y, et al: HPV E6/E7 promotes aerobic
glycolysis in cervical cancer by regulating IGF2BP2 to stabilize
m6A-MYC expression. Int J Biol Sci. 18:507–521. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Jiang X, Guo S, Wang S, Zhang Y, Chen H,
Wang Y, Liu R, Niu Y and Xu Y: EIF4A3-induced circARHGAP29 promotes
aerobic glycolysis in docetaxel-resistant prostate cancer through
IGF2BP2/c-Myc/LDHA signaling. Cancer Res. 82:831–845. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Lu S, Han L, Hu X, Sun T, Xu D, Li Y, Chen
Q, Yao W, He M, Wang Z, et al: N6-methyladenosine reader IMP2
stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect:
Implication in colorectal cancer. J Hematol Oncol. 14:1882021.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Qiu X, Xu Q, Liao B, Hu S, Zhou Y and
Zhang H: Circ-CCS regulates oxaliplatin resistance via targeting
miR-874-3p/HK2 axis in colorectal cancer. Histol Histopathol.
38:1145–1156. 2023.PubMed/NCBI
|
|
124
|
Wang Z, Wang MM, Geng Y, Ye CY and Zang
YS: Membrane-associated RING-CH protein (MARCH8) is a novel
glycolysis repressor targeted by miR-32 in colorectal cancer. J
Transl Med. 20:4022022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Xu K, Dai X, Wu J and Wen K:
N6-methyladenosine (m6A) reader IGF2BP2
stabilizes HK2 stability to accelerate the Warburg effect of oral
squamous cell carcinoma progression. J Cancer Res Clin Oncol.
148:3375–3384. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Liu H, Qin S, Liu C, Jiang L, Li C, Yang
J, Zhang S, Yan Z, Liu X, Yang J and Sun X: m6A reader
IGF2BP2-stabilized CASC9 accelerates glioblastoma aerobic
glycolysis by enhancing HK2 mRNA stability. Cell Death Discov.
7:2922021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ye M, Chen J, Lu F, Zhao M, Wu S, Hu C, Yu
P, Kan J, Bai J, Tian Y and Tang Q: Down-regulated FTO and ALKBH5
co-operatively activates FOXO signaling through m6A methylation
modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis
in colorectal cancer. Cell Biosci. 13:1482023. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Chen J, Ye M, Bai J, Gong Z, Yan L, Gu D,
Hu C, Lu F, Yu P, Xu L, et al: ALKBH5 enhances lipid metabolism
reprogramming by increasing stability of FABP5 to promote
pancreatic neuroendocrine neoplasms progression in an
m6A-IGF2BP2-dependent manner. J Transl Med. 21:7412023. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Chandra J, Hansen M, Labarriere N, Marigo
I, Souza-Fonseca-Guimaraes F, Vujanovic L, Koguchi Y and Jacquelot
N: Editorial: Cancer immunotherapies: From efficacy to resistance
mechanisms. Front Immunol. 13:9397892022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Elcheva IA, Gowda CP, Bogush D,
Gornostaeva S, Fakhardo A, Sheth N, Kokolus KM, Sharma A, Dovat S,
Uzun Y, et al: IGF2BP family of RNA-binding proteins regulate
innate and adaptive immune responses in cancer cells and tumor
microenvironment. Front Immunol. 14:12245162023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Liu T, Han C, Hu C, Mao S, Sun Y, Yang S
and Yang K: Knockdown of IGF2BP2 inhibits colorectal cancer cell
proliferation, migration and promotes tumor immunity by
down-regulating MYC expression. Xi Bao Yu Fen Zi Mian Yi Xue Za
Zhi. 39:303–310. 2023.(In Chinese). PubMed/NCBI
|
|
132
|
Liu QZ, Zhang N, Chen JY, Zhou MJ, Zhou
DH, Chen Z, Huang ZX, Xie YX, Qiao GL and Tu XH: WTAP-induced
N6-methyladenosine of PD-L1 blocked T-cell-mediated
antitumor activity under hypoxia in colorectal cancer. Cancer Sci.
115:1749–1762. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Liu Y, Shi M, He X, Cao Y, Liu P, Li F,
Zou S, Wen C, Zhan Q, Xu Z, et al: LncRNA-PACERR induces pro-tumour
macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2
in pancreatic ductal adenocarcinoma. J Hematol Oncol. 15:522022.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Li S, Wu Q, Liu J and Zhong Y:
Identification of two m6A Readers YTHDF1 and IGF2BP2 as immune
biomarkers in head and neck squamous cell carcinoma. Front Genet.
13:9036342022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Zhou L, Li H, Cai H, Liu W, Pan E, Yu D
and He S: Upregulation of IGF2BP2 promotes oral squamous cell
carcinoma progression that is related to cell proliferation,
metastasis and tumor-infiltrating immune cells. Front Oncol.
12:8095892022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Zhu L, Liu Y, Tang H and Wang P: FOXP3
activated-LINC01232 accelerates the stemness of non-small cell lung
carcinoma by activating TGF-β signaling pathway and recruiting
IGF2BP2 to stabilize TGFBR1. Exp Cell Res. 413:1130242022.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Huang C, Xu R, Zhu X and Jiang H:
m6A-modified circABCC4 promotes stemness and metastasis of prostate
cancer by recruiting IGF2BP2 to increase stability of CCAR1. Cancer
Gene Ther. 30:1426–1440. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Ji R, Wu C, Yao J, Xu J, Lin J, Gu H, Fu M
and Zhang X, Li Y and Zhang X: IGF2BP2-meidated m6A
modification of CSF2 reprograms MSC to promote gastric cancer
progression. Cell Death Dis. 14:6932023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Janiszewska M, Suvà ML, Riggi N,
Houtkooper RH, Auwerx J, Clément-Schatlo V, Radovanovic I, Rheinbay
E, Provero P and Stamenkovic I: Imp2 controls oxidative
phosphorylation and is crucial for preserving glioblastoma cancer
stem cells. Genes Dev. 26:1926–1944. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Degrauwe N, Schlumpf TB, Janiszewska M,
Martin P, Cauderay A, Provero P, Riggi N, Suvà ML, Paro R and
Stamenkovic I: The RNA binding protein IMP2 preserves glioblastoma
stem cells by preventing let-7 target gene silencing. Cell Rep.
15:1634–1647. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Cui Y, Wen Y, Lv C, Zhao D, Yang Y, Qiu H
and Wang C: Decreased RNA-binding protein IGF2BP2 downregulates
NT5DC2, which suppresses cell proliferation, and induces cell cycle
arrest and apoptosis in diffuse large B-cell lymphoma cells by
regulating the p53 signaling pathway. Mol Med Rep. 26:2862022.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Ye J, Wu Y, Chen Y, Ren Y, Jiang X, Dong
Z, Zhang J, Jin M, Chen X, Wang Z and Xiao M: ALKBH5 promotes
hypopharyngeal squamous cell carcinoma apoptosis by targeting TLR2
in a YTHDF1/IGF2BP2-mediated manner. Cell Death Discov. 9:3082023.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Yang X and Liu J: Targeting PD-L1
(Programmed death-ligand 1) and inhibiting the expression of
IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2)
affect the proliferation and apoptosis of hypopharyngeal carcinoma
cells. Bioengineered. 12:7755–7764. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Kessler SM, Pokorny J, Zimmer V, Laggai S,
Lammert F, Bohle RM and Kiemer AK: IGF2 mRNA binding protein
p62/IMP2-2 in hepatocellular carcinoma: Antiapoptotic action is
independent of IGF2/PI3K signaling. Am J Physiol Gastrointest Liver
Physiol. 304:G328–G336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Zheng X, Wu J, Song L and Huang B: ACSM3
suppresses proliferation and induces apoptosis and cell cycle
arrest in acute myeloid leukemia cells via the regulation of
IGF2BP2. Exp Ther Med. 25:1772023. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Dixon SJ: Ferroptosis: Bug or feature?
Immunol Rev. 277:150–157. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao
N, Sun B and Wang G: Ferroptosis: Past, present and future. Cell
Death Dis. 11:882020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Jiang X, Stockwell BR and Conrad M:
Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol
Cell Biol. 22:266–282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Yang R, Wan J, Ma L, Zhou F, Yang Z, Li Z,
Zhang M and Ming L: TMEM44-AS1 promotes esophageal squamous cell
carcinoma progression by regulating the IGF2BP2-GPX4 axis in
modulating ferroptosis. Cell Death Discov. 9:4312023. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Ye J, Chen X, Jiang X, Dong Z, Hu S and
Xiao M: RNA demethylase ALKBH5 regulates hypopharyngeal squamous
cell carcinoma ferroptosis by posttranscriptionally activating
NFE2L2/NRF2 in an m6 A-IGF2BP2-dependent manner. J Clin
Lab Anal. 36:e245142022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Bian Y, Xu S, Gao Z, Ding J, Li C, Cui Z,
Sun H, Li J, Pu J and Wang K: m6A modification of lncRNA
ABHD11-AS1 promotes colorectal cancer progression and inhibits
ferroptosis through TRIM21/IGF2BP2/FOXM1 positive feedback loop.
Cancer Lett. 596:2170042024. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Jung YD, Ahmad SA, Liu W, Reinmuth N,
Parikh A, Stoeltzing O, Fan F and Ellis LM: The role of the
microenvironment and intercellular cross-talk in tumor
angiogenesis. Semin Cancer Biol. 12:105–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Wang Y, Sun H, Zhang D, Fan D, Zhang Y,
Dong X, Liu S, Yang Z, Ni C, Li Y, et al: TP53INP1 inhibits
hypoxia-induced vasculogenic mimicry formation via the ROS/snail
signalling axis in breast cancer. J Cell Mol Med. 22:3475–3488.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Ma YS, Shi BW, Guo JH, Liu JB, Yang XL,
Xin R, Shi Y, Zhang DD, Lu GX, Jia CY, et al: microRNA-320b
suppresses HNF4G and IGF2BP2 expression to inhibit angiogenesis and
tumor growth of lung cancer. Carcinogenesis. 42:762–771. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Fang H, Sun Q, Zhou J, Zhang H, Song Q,
Zhang H, Yu G, Guo Y, Huang C, Mou Y, et al: m6A
methylation reader IGF2BP2 activates endothelial cells to promote
angiogenesis and metastasis of lung adenocarcinoma. Mol Cancer.
22:992023. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
He Z, Zhong Y, Regmi P, Lv T, Ma W, Wang
J, Liu F, Yang S, Zhong Y, Zhou R, et al: Exosomal long non-coding
RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through
interacting with PABPC1 to activate NOTCH1 signaling pathway. Mol
Cancer. 23:652024. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Xu S, Bai J, Zhuan Z, Li B, Zhang Z, Wu X,
Luo X and Yang L: EBV-LMP1 is involved in vasculogenic mimicry
formation via VEGFA/VEGFR1 signaling in nasopharyngeal carcinoma.
Oncol Rep. 40:377–384. 2018.PubMed/NCBI
|
|
159
|
Yang Z, Sun B, Li Y, Zhao X, Zhao X, Gu Q,
An J, Dong X, Liu F and Wang Y: ZEB2 promotes vasculogenic mimicry
by TGF-β1 induced epithelial-to-mesenchymal transition in
hepatocellular carcinoma. Exp Mol Pathol. 98:352–359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Taddei ML, Parri M, Angelucci A, Bianchini
F, Marconi C, Giannoni E, Raugei G, Bologna M, Calorini L and
Chiarugi P: EphA2 induces metastatic growth regulating amoeboid
motility and clonogenic potential in prostate carcinoma cells. Mol
Cancer Res. 9:149–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Yao X, Ping Y, Liu Y, Chen K, Yoshimura T,
Liu M, Gong W, Chen C, Niu Q, Guo D, et al: Vascular endothelial
growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic
mimicry formation, neovascularization and tumor initiation by
glioma stem-like cells. PLoS One. 8:e571882013. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Liu X, He H, Zhang F, Hu X, Bi F, Li K, Yu
H, Zhao Y, Teng X, Li J, et al: m6A methylated EphA2 and VEGFA
through IGF2BP2/3 regulation promotes vasculogenic mimicry in
colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death
Dis. 13:4832022. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Li H, Wang D, Yi B, Cai H, Wang Y, Lou X,
Xi Z and Li Z: SUMOylation of IGF2BP2 promotes vasculogenic mimicry
of glioma via regulating OIP5-AS1/miR-495-3p axis. Int J Biol Sci.
17:2912–2930. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Sa R, Liang R, Qiu X, He Z, Liu Z and Chen
L: Targeting IGF2BP2 promotes differentiation of radioiodine
refractory papillary thyroid cancer via destabilizing RUNX2 mRNA.
Cancers (Basel). 14:12682022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Sa R, Guo M, Liu D and Guan F: AhR
antagonist promotes differentiation of papillary thyroid cancer via
regulating circSH2B3/miR-4640-5P/IGF2BP2 axis. Front Pharmacol.
12:7953862021. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Dahlem C, Abuhaliema A, Kessler SM,
Kröhler T, Zoller BGE, Chanda S, Wu Y, Both S, Müller F, Lepikhov
K, et al: First small-molecule inhibitors targeting the RNA-binding
protein IGF2BP2/IMP2 for cancer therapy. ACS Chem Biol. 17:361–375.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Weng H, Huang F, Yu Z, Chen Z, Prince E,
Kang Y, Zhou K, Li W, Hu J, Fu C, et al: The m6A reader
IGF2BP2 regulates glutamine metabolism and represents a therapeutic
target in acute myeloid leukemia. Cancer Cell. 40:1566–1582.e10.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Chanda S, Lepikhov K, Dahlem C, Schymik
HS, Hoppstädter J, Geber AK, Wagner K, Kessler SM, Empting M and
Kiemer AK: Gene editing and small molecule inhibitors of the RNA
binding protein IGF2BP2/IMP2 show its potential as an anti-cancer
drug target. Front Biosci (Landmark Ed). 29:412024. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Winkle M, El-Daly SM, Fabbri M and Calin
GA: Noncoding RNA therapeutics-challenges and potential solutions.
Nat Rev Drug Discov. 20:629–651. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Toden S, Zumwalt TJ and Goel A: Non-coding
RNAs and potential therapeutic targeting in cancer. Biochim Biophys
Acta Rev Cancer. 1875:1884912021. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Ye M, Dong S, Hou H, Zhang T and Shen M:
Oncogenic role of long noncoding RNAMALAT1 in thyroid cancer
progression through regulation of the miR-204/IGF2BP2/m6A-MYC
signaling. Mol Ther Nucleic Acids. 23:1–12. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Liu FY, Zhou SJ, Deng YL, Zhang ZY, Zhang
EL, Wu ZB, Huang ZY and Chen XP: MiR-216b is involved in
pathogenesis and progression of hepatocellular carcinoma through
HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis.
6:e16702015. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Xiao Y, Tang J, Yang D, Zhang B, Wu J, Wu
Z, Liao Q, Wang H, Wang W and Su M: Long noncoding RNA LIPH-4
promotes esophageal squamous cell carcinoma progression by
regulating the miR-216b/IGF2BP2 axis. Biomark Res. 10:602022.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Wu X, Fan Y, Liu Y, Shen B, Lu H and Ma H:
Long non-coding RNA CCAT2 promotes the development of esophageal
squamous cell carcinoma by inhibiting miR-200b to upregulate the
IGF2BP2/TK1 axis. Front Oncol. 11:6806422021. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Fen H, Hongmin Z, Wei W, Chao Y, Yang Y,
Bei L and Zhihua S: RHPN1-AS1 drives the progression of
hepatocellular carcinoma via regulating miR-596/IGF2BP2 axis. Curr
Pharm Des. 25:4630–4640. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Zhu X, Yu H, Li H, Zhang W, Sun L, Dou T,
Wang Z, Zhao H and Yang H: lncRNA SNHG1 promotes the progression of
hepatocellular carcinoma by regulating the miR-7-5p/IGF2BP2 axis.
Heliyon. 10:e276312024. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Yao B, Zhang Q, Yang Z, An F, Nie H, Wang
H, Yang C, Sun J, Chen K, Zhou J, et al: CircEZH2/miR-133b/IGF2BP2
aggravates colorectal cancer progression via enhancing the
stability of m6A-modified CREB1 mRNA. Mol Cancer.
21:1402022. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Yang Y, Liu X, Cheng L, Li L, Wei Z, Wang
Z, Han G, Wan X, Wang Z, Zhang J and Chen C: Tumor suppressor
microRNA-138 suppresses low-grade glioma development and metastasis
via regulating IGF2BP2. Onco Targets Ther. 13:2247–2260. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Ding L, Wang L and Guo F: microRNA-188
acts as a tumour suppressor in glioma by directly targeting the
IGF2BP2 gene. Mol Med Rep. 16:7124–7130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Huang RS, Zheng YL, Li C, Ding C, Xu C and
Zhao J: MicroRNA-485-5p suppresses growth and metastasis in
non-small cell lung cancer cells by targeting IGF2BP2. Life Sci.
199:104–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Liao S, Sun H and Xu C: YTH domain: A
family of N6-methyladenosine (m6A) readers.
Genomics Proteomics Bioinformatics. 16:99–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Wang Q, Geng W, Guo H, Wang Z, Xu K, Chen
C and Wang S: Emerging role of RNA methyltransferase METTL3 in
gastrointestinal cancer. J Hematol Oncol. 13:572020. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Jumper J, Evans R, Pritzel A, Green T,
Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A,
Potapenko A, et al: Highly accurate protein structure prediction
with AlphaFold. Nature. 596:583–589. 2021. View Article : Google Scholar : PubMed/NCBI
|
